Figure 6. Targeting MDSC subset-associated suppressive pathways blocks tumor growth.

A. Accumulation of G-MDSC (CD11b⁺Ly6C^LOW Ly6G^HIGH) and Mo-MDSC (CD11b⁺ Ly6C^HIGH Ly6G^NEG-LOW) in tumors from mice injected with 3LL, B16, EL-4, or MCA-38 tumors. B. A representative experiment showing higher numbers of G-MDSC in 3LL tumors (n=10) and the preferential accumulation of Mo-MDSC in MCA-38 tumors (n=10). C. 3LL (upper panel) or MCA-38 (lower panel) cells were subcutaneously injected into wild-type and gp91^phox−/− mice and tumor volume measured daily (n=10). D. To determine the role of PNT production on tumor burden, mice were subcutaneously injected with 3LL or MCA-38 cells and treated daily with the PNT scanvenger (MnTBAP) or PBS control (n=10). E. iNOS−/− mice were injected with 3LL or MCA-38 cells and their growth compared with wild type mice (n=10). * p < 0.01, Non-statistical significant differences (ns): p > 0.05